{'fraction_non_alphanumeric': 0.028116213683223992, 'fraction_numerical': 0.013120899718837863, 'mean_word_length': 5.633540372670807, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Clinical analysis of ofloxacin in treatment of postinfectious exacerbations of endogenous bronchial asthma].

The aim of the study was to analyse the clinical effectiveness of ofloxacin in treatment of post-infectious exacerbations of endogenous bronchial asthma. Twenty eight patients (20 males, 8 females) were assessed. The following parameters were evaluated: bacteriological examination of the sputum (before and after treatment), morphological analysis of peripheral blood, bronchoalveolar lavage (performed in 11 patients). Additionally in 7 patients lymphocyte subpopulations of the peripheral blood were determined (OKT4/OKT8). Diurnal variations of serum levels of theophylline were assessed in 12 patients. The authors observed a clinical improvement in 26 patients. Following treatment the white cell blood count (WBC) and the CD4/CD8 ratio decreased. The same observations were made analysing the BAL differential count, in which a marked decrease of neutrophils was seen. The authors conclude that ofloxacin is a safe and efficient antimicrobial agent.